Discover our news & insights.
Follow the latest developments at BIMINI Biotech, including research updates, pipeline progress, company milestones and collaborations as we advance our WASp-targeting programmes toward the clinic.
BIMINI Biotech closes new seed round with Libertatis Ergo Holding for the development of first-in-class therapeutics
Leiden, 29 June 2023. BIMINI Biotech has raised an additional €250,000 investment from Libertatis Ergo Holding B.V. to support the development of first-in-class therapeutics for haematological cancers. The financing will be combined with Eurostars funding to advance...
BIMINI Biotech closes new seed round with Libertatis Ergo Holding for the development of first-in-class therapeutics
Leiden, 29 June 2023. BIMINI Biotech has raised an additional €250,000 investment from Libertatis Ergo Holding B.V. to support the development of first-in-class therapeutics for haematological cancers. The financing will be combined with Eurostars funding to advance...
BIMINI Biotech raises a EUR3M seed round to advance first-in-class therapeutics for hematological cancers
Leiden, 8 January 2025. BIMINI Biotech has closed a €3 million seed investment round to advance its first-in-class therapeutics for haematological cancers. The financing was led by San Diego-based Torrey Pines Investment, with participation from InnovationQuarter...
Dr. Helmuth van Es joins Supervisory Board
Leiden, 6 January 2026. BIMINI Biotech has appointed Dr. Helmuth van Es as an Independent Supervisory Board Member. Dr. van Es brings more than 30 years of experience in biotechnology, drug discovery and development, company building and strategic leadership. He began...
BIMINI welcomes Prof. Nathaniel Martin as advisor chemistry
BIMINI Biotech has welcomed Prof. Nathaniel Martin as an advisor in chemistry, supporting the lead optimisation of the company's small-molecule WASp modulators. Prof. Martin is Professor of Biological Chemistry at Leiden University. He obtained his PhD from the...
BIMINI Biotech’s MIT Feasibility grant AUTO-WASP awarded
BIMINI Biotech has received a €20,000 MIT feasibility grant for the AUTO-WASP project, supporting an assessment of WASp modulation as a potential therapeutic approach in autoimmune disease. The Mkb-innovatiestimulering Regio en Topsectoren programme supports...
BIMINI Biotech awarded Health Holland International Kickstarter grant to advance novel AML therapeutics
Leiden, 18 March 2026. BIMINI Biotech has been awarded funding through the Health Holland International Kickstarter Call for Public-Private Partnerships for a project advancing first-in-class therapeutics for acute myeloid leukaemia. The €440,000 AML-WASP project...
BIMINI Biotech secures Eurostars grant for MYELO-WASP project to develop first-in-class leukemia therapeutics
Leiden, 9 April 2026. The MYELO-WASP project has been awarded funding through the Eureka Eurostars programme to advance first-in-class small molecules targeting Wiskott-Aldrich Syndrome Protein (WASp) for myeloid and lymphoid leukaemias. The €2.2 million international...
BIMINI Biotech and Radboudumc awarded Health Holland SME grant to advance novel therapeutics for autoimmune diseases
Leiden, 11 September 2026. BIMINI Biotech and Radboudumc have been awarded a Health Holland SME grant for AUTO-WASP, a collaborative project exploring a novel therapeutic approach targeting the Wiskott-Aldrich Syndrome Protein (WASp) in autoimmune and inflammatory...
Website copy
One target. Two therapeutic directions. BIMINI develops first-in-class small molecule modulators of WASp for oncology and autoimmune disease. By activating or inhibiting the same biological target, we are building distinct therapeutic approaches around a central...
Hello world!
Welcome to WordPress. This is your first post. Edit or delete it, then start writing!